Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors
- PMID: 11074211
- DOI: 10.1016/s0002-9149(00)01171-1
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors
Erratum in
- Am J Cardiol 2001 May 1;87(9):1138
Abstract
The purpose of this study was to determine if long-term use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (atorvastatin, fluvastatin, lovastatin, pravastatin, or simvastatin) resulted in tachyphylaxis (a decreasing response to a physiologically active agent). To determine this, the charts of 254 patients treated with statins from the years 1996 to 1998 were retrospectively reviewed. During treatment, the low-density lipoprotein (LDL) cholesterol levels of patients were followed for a minimum of 300 days. To characterize LDL cholesterol changes during statin therapy, linear and nonlinear kinetic models were generated. Tachyphylaxis, defined as a positive slope of LDL cholesterol over time, after maximum LDL cholesterol reduction, was identified in patients treated with atorvastatin at exposure doses of 10 or 20 mg/day. All other statins, at all doses reviewed, showed no [corrected] evidence of tachyphylaxis. LDL cholesterol tachyphylaxis appeared to be a unique response to prolonged use of long half-life atorvastatin therapy at exposure dosages.
Comment in
-
Tachyphylaxis and statin drugs.Am J Cardiol. 2001 Mar 1;87(5):674. doi: 10.1016/s0002-9149(01)01456-4. Am J Cardiol. 2001. PMID: 11245286 No abstract available.
-
Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.Am J Cardiol. 2001 Apr 15;87(8):1032-4. doi: 10.1016/s0002-9149(01)01543-0. Am J Cardiol. 2001. PMID: 11327075 No abstract available.
-
Development of tachyphylaxis on statin treatment.Am J Cardiol. 2001 Oct 15;88(8):936-7. Am J Cardiol. 2001. PMID: 11676971 No abstract available.
Similar articles
-
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).Am J Cardiol. 1998 Mar 1;81(5):582-7. doi: 10.1016/s0002-9149(97)00965-x. Am J Cardiol. 1998. PMID: 9514454 Clinical Trial.
-
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.Am J Geriatr Pharmacother. 2007 Sep;5(3):185-94. doi: 10.1016/j.amjopharm.2007.10.002. Am J Geriatr Pharmacother. 2007. PMID: 17996658
-
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.Am J Cardiovasc Drugs. 2006;6(3):177-88. doi: 10.2165/00129784-200606030-00005. Am J Cardiovasc Drugs. 2006. PMID: 16780391
-
Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.Clin Pharmacokinet. 1997 May;32(5):403-25. doi: 10.2165/00003088-199732050-00005. Clin Pharmacokinet. 1997. PMID: 9160173 Review.
-
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.Drugs. 2001;61(12):1835-81. doi: 10.2165/00003495-200161120-00012. Drugs. 2001. PMID: 11693468 Review.
Cited by
-
Lipoprotein changes with statins.Curr Atheroscler Rep. 2002 Jan;4(1):14-8. doi: 10.1007/s11883-002-0057-8. Curr Atheroscler Rep. 2002. PMID: 11772417 Review.
-
Parkinson's disease: is the initial treatment established?Curr Neurol Neurosci Rep. 2003 Jul;3(4):289-95. doi: 10.1007/s11910-003-0005-1. Curr Neurol Neurosci Rep. 2003. PMID: 12930698 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical